Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
Hepion Pharmaceuticals (HEPA) announced that results from its Phase 2a AMBITION NASH trial will be available as an e-poster at the virtual Liver Meeting® 2021 from November 12-15, 2021. The trial, involving 43 patients, focused on CRV431 administration and successfully met all primary endpoints, demonstrating safety and pharmacokinetics. The trial's findings suggest the efficacy of CRV431 for treating NASH. Additionally, Hepion plans to utilize its AI-POWR™ platform to optimize patient response and explore further indications for CRV431.
- Successful completion of all primary endpoints in the Phase 2a AMBITION trial, confirming safety and pharmacokinetics of CRV431.
- Efficacy indications for CRV431 in treating NASH, a significant market opportunity.
- Use of proprietary AI-POWR™ platform to enhance patient treatment outcomes and expedite drug development.
- None.
EDISON, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and other liver diseases, today announced that results from its Phase 2a ‘AMBITION’ NASH trial will be available as an e-poster at the Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), to be held virtually November 12-15, 2021.
Poster Details
- Poster #: 1872
- Title: Investigating CRV431 in NASH Patients: Data from the Phase 2a AMBITION Study
- Session: 2304 - NAFLD AND NASH: EXPERIMENTAL: CLINICAL
- Lead Author: Stephen Harrison, MD, Medical Director for Pinnacle Clinical Research, San Antonio, Texas, and Visiting Professor of Hepatology, Oxford University.
The meeting platform with posters is now open and the e-poster is also available on the publications page of the Company’s website.
About the Phase 2a AMBITION Clinical Trial
AMBITION, a multicenter, randomized, placebo controlled, single-blind Phase 2a trial, enrolled 43 NASH patients. The trial was designed to investigate once daily oral administration of CRV431 at doses of 75 mg (n=12) and 225 mg (n=17) administered as soft gelatin capsules to presumed F2 and F3 NASH subjects for 28 days, followed by a 14-day observation period for safety.
All primary endpoints of the AMBITION NASH trial (safety, tolerability and pharmacokinetics) were met, and changes in select biomarkers indicated efficacy of CRV431.
About Hepion Pharmaceuticals
The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies.
Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing NASH clinical development program, Hepion intends to use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on Hepion Pharmaceuticals’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2020, and other periodic reports filed with the Securities and Exchange Commission.
For further information, please contact:
Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com
FAQ
What are the results of Hepion Pharmaceuticals' Phase 2a AMBITION trial for CRV431?
Where can I find the e-poster for the AMBITION NASH trial results by Hepion Pharmaceuticals?
What is the focus of Hepion Pharmaceuticals' AI-POWR™ platform?
When is the virtual Liver Meeting® 2021 where Hepion Pharmaceuticals will present its findings?
How many patients were enrolled in the Phase 2a AMBITION trial?
